Michail Varras
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Michail Varras has a total of 150 co-authors. Here are the top co-authors by number of shared publications:
Ch Akrivis
22 shared publications- Fani-Niki Varra
Department of Pharmacy, School of Health Sciences, Frederick University, Nicosia 1036, Cyprus
14 shared publications - Viktoria-Konstantina Varra
Department of Pharmacy, School of Health Sciences, University of Patras, University Campus, 26504 Patra, Greece
14 shared publications N Antoniou
12 shared publications- Panagiotis Theodosis-Nobelos
Department of Pharmacy, School of Health Sciences, Frederick University, Nicosia 1036, Cyprus
12 shared publications D Polyzos
9 shared publications
Latest Publications
- Open Access
The Molecular Landscape of Placental Dysfunction in Fetal Growth Restriction (FGR): From Integrated Signaling Networks to Epigenetic Control
Fetal growth restriction (FGR) is a major pregnancy complication linked to placental insufficiency, resulting from defective trophoblast differentiation, impaired maternal–fetal vascular adaptation, and altered nutrient sensing. This review synthesizes current evidence on the interconnected molecular networks driving placental dysfunction. We map the reciprocal crosstalk between the pro-inflammatory shift, highlighted by NLRP3 inflammasome-driven trophoblast pyroptosis, and dysregulated extracellular matrix remodeling mediated by the MMP-9/TIMP system. This hostile microenvironment feeds directly into the angiogenic imbalance defined by the sFlt-1/PlGF ratio, accelerating cellular senescence via p53 and disrupting survival hubs like the PTEN/PI3K/AKT axis. Consequently, downstream metabolic sensors, notably the mTOR pathway, are blunted, causing trafficking failure of essential amino acid (SNAT2, LAT1) and glucose (GLUT) transporters. Crucially, we introduce an original framework integrating emerging spatial transcriptomics and single-cell epigenomics, demonstrating that these pathomechanisms are anatomically regionalized rather than uniform. Finally, we provide a critical evaluation of translation-ready therapeutic targets, emphasizing that strict safety constraints against fetal teratogenesis render ligand-functionalized nanoparticles a non-negotiable prerequisite for placenta-selective drug delivery. Integrating molecular stratification with longitudinal biomarker profiling represents the next milestone for mechanism-based, targeted management of FGR.
Open AccessThe Molecular Landscape of Placental Dysfunction in Fetal Growth Restriction (FGR): From Integrated Signaling Networks to Epigenetic Control
Fetal growth restriction (FGR) is a major pregnancy complication linked to placental insufficiency, resulting from defective trophoblast differentiation, impaired maternal–fetal vascular adaptation, and altered nutrient sensing. This review synthesizes current evidence on the interconnected molecular networks driving placental dysfunction. We map the reciprocal crosstalk between the pro-inflammatory shift, highlighted by NLRP3 inflammasome-driven trophoblast pyroptosis, and dysregulated extracellular matrix remodeling mediated by the MMP-9/TIMP system. This hostile microenvironment feeds directly into the angiogenic imbalance defined by the sFlt-1/PlGF ratio, accelerating cellular senescence via p53 and disrupting survival hubs like the PTEN/PI3K/AKT axis. Consequently, downstream metabolic sensors, notably the mTOR pathway, are blunted, causing trafficking failure of essential amino acid (SNAT2, LAT1) and glucose (GLUT) transporters. Crucially, we introduce an original framework integrating emerging spatial transcriptomics and single-cell epigenomics, demonstrating that these pathomechanisms are anatomically regionalized rather than uniform. Finally, we provide a critical evaluation of translation-ready therapeutic targets, emphasizing that strict safety constraints against fetal teratogenesis render ligand-functionalized nanoparticles a non-negotiable prerequisite for placenta-selective drug delivery. Integrating molecular stratification with longitudinal biomarker profiling represents the next milestone for mechanism-based, targeted management of FGR.
- Open Access
- 30 October 2026
- Published by MDPI AG in Preprints.org
Redox Imbalance and Antioxidant Defense in Fetal Growth Restriction (FGR): Pathophysiological Mechanisms, Biomarkers, and Therapeutic Perspectives
Fetal growth restriction (FGR) is a major obstetric complication associated with increased perinatal morbidity, mortality, and adverse long-term metabolic outcomes in adulthood. Placental dysfunction stands as the principal driver in a substantial proportion of cases, with accumulating evidence indicating that the disruption of placental redox homeostasis plays a central role in its pathophysiology. This review provides a comprehensive synthesis of redox dysregulation in FGR, extending beyond classical oxidative injury to incorporate emerging non-linear paradigms. Excessive production of reactive oxygen species (ROS), coupled with inadequate antioxidant defenses, promotes lipid, protein, and DNA damage, thereby impairing trophoblast function, vascular remodeling, cell survival, and nutrient transport. Crucially, this review integrates recent breakthroughs in the fields of iron-dependent ferroptosis, endoplasmic reticulum stress, and complex redox-epigenetic cross-talk mediated by non-coding RNAs ("redox-miRs"). Furthermore, we address the translational failure of conventional systemic antioxidant therapies, highlighting the newly recognized paradox of reductive stress, where over-supplementation disrupts essential ROS-dependent signaling cascades during early placentation. To resolve these diagnostic and therapeutic limitations, this work evaluates the clinical utility of multi-omics integration for mapping placental metabolic reprogramming and artificial intelligence (AI) machine learning models that combine maternal serum redox biomarkers with longitudinal fetal Doppler metrics for early risk stratification. Finally, we explore next-generation obstetric frontiers, including placenta-targeted nanomedicine for localized drug delivery, Placenta-on-a-Chip microfluidic and organoid screening platforms, and autologous mitochondrial transplantation aimed at rescuing syncytiotrophoblast bioenergetics. Overall, current evidence underscores placental redox dysregulation as an interconnected, systemic failure rather than an isolated molecular defect. Moving toward precision, redox-guided perinatal management requires longitudinal human studies and well-designed clinical trials to validate whether the targeted restoration of redox homeostasis can translate into improved maternal, fetal, and neonatal outcomes.
- 30 October 2026
- Published by MDPI AG in Preprints.org
Open AccessRedox Imbalance and Antioxidant Defense in Fetal Growth Restriction (FGR): Pathophysiological Mechanisms, Biomarkers, and Therapeutic Perspectives
Fetal growth restriction (FGR) is a major obstetric complication associated with increased perinatal morbidity, mortality, and adverse long-term metabolic outcomes in adulthood. Placental dysfunction stands as the principal driver in a substantial proportion of cases, with accumulating evidence indicating that the disruption of placental redox homeostasis plays a central role in its pathophysiology. This review provides a comprehensive synthesis of redox dysregulation in FGR, extending beyond classical oxidative injury to incorporate emerging non-linear paradigms. Excessive production of reactive oxygen species (ROS), coupled with inadequate antioxidant defenses, promotes lipid, protein, and DNA damage, thereby impairing trophoblast function, vascular remodeling, cell survival, and nutrient transport. Crucially, this review integrates recent breakthroughs in the fields of iron-dependent ferroptosis, endoplasmic reticulum stress, and complex redox-epigenetic cross-talk mediated by non-coding RNAs ("redox-miRs"). Furthermore, we address the translational failure of conventional systemic antioxidant therapies, highlighting the newly recognized paradox of reductive stress, where over-supplementation disrupts essential ROS-dependent signaling cascades during early placentation. To resolve these diagnostic and therapeutic limitations, this work evaluates the clinical utility of multi-omics integration for mapping placental metabolic reprogramming and artificial intelligence (AI) machine learning models that combine maternal serum redox biomarkers with longitudinal fetal Doppler metrics for early risk stratification. Finally, we explore next-generation obstetric frontiers, including placenta-targeted nanomedicine for localized drug delivery, Placenta-on-a-Chip microfluidic and organoid screening platforms, and autologous mitochondrial transplantation aimed at rescuing syncytiotrophoblast bioenergetics. Overall, current evidence underscores placental redox dysregulation as an interconnected, systemic failure rather than an isolated molecular defect. Moving toward precision, redox-guided perinatal management requires longitudinal human studies and well-designed clinical trials to validate whether the targeted restoration of redox homeostasis can translate into improved maternal, fetal, and neonatal outcomes.
- Open Access
- 9 October 2026
- Published by MDPI AG in Preprints.org
The Molecular Landscape of Placental Dysfunction in Fetal Growth Restriction (FGR): From Integrated Signaling Networks to Epigenetic Control
Fetal growth restriction (FGR) is a major pregnancy complication linked to placental insufficiency, resulting from defective trophoblast differentiation, impaired maternal-fetal vascular adaptation, and altered nutrient sensing. This review synthesizes current evidence on the interconnected molecular networks driving placental dysfunction. We map the reciprocal crosstalk between the pro-inflammatory shift, highlighted by NLRP3 inflammasome-driven trophoblast pyroptosis, and dysregulated extracellular matrix remodeling mediated by the MMP-9/TIMP system. This hostile microenvironment feeds directly into the angiogenic imbalance defined by the sFlt-1/PlGF ratio, accelerating cellular senescence via p53 and disrupting survival hubs like the PTEN/PI3K/AKT axis. Consequently, downstream metabolic sensors, notably the mTOR pathway, are blunted, causing trafficking failure of essential amino acid (SNAT2, LAT1) and glucose (GLUT) transporters. Crucially, we introduce an original framework integrating emerging spatial transcriptomics and single-cell epigenomics, demonstrating that these pathomechanisms are anatomically regionalized rather than uniform. Finally, we provide a critical evaluation of translation-ready therapeutic targets, emphasizing that strict safety constraints against fetal teratogenesis render ligand-functionalized nanoparticles a non-negotiable prerequisite for placenta-selective drug delivery. Integrating molecular stratification with longitudinal biomarker profiling represents the next milestone for mechanism-based, targeted management of FGR.
- 9 October 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Molecular Landscape of Placental Dysfunction in Fetal Growth Restriction (FGR): From Integrated Signaling Networks to Epigenetic Control
Fetal growth restriction (FGR) is a major pregnancy complication linked to placental insufficiency, resulting from defective trophoblast differentiation, impaired maternal-fetal vascular adaptation, and altered nutrient sensing. This review synthesizes current evidence on the interconnected molecular networks driving placental dysfunction. We map the reciprocal crosstalk between the pro-inflammatory shift, highlighted by NLRP3 inflammasome-driven trophoblast pyroptosis, and dysregulated extracellular matrix remodeling mediated by the MMP-9/TIMP system. This hostile microenvironment feeds directly into the angiogenic imbalance defined by the sFlt-1/PlGF ratio, accelerating cellular senescence via p53 and disrupting survival hubs like the PTEN/PI3K/AKT axis. Consequently, downstream metabolic sensors, notably the mTOR pathway, are blunted, causing trafficking failure of essential amino acid (SNAT2, LAT1) and glucose (GLUT) transporters. Crucially, we introduce an original framework integrating emerging spatial transcriptomics and single-cell epigenomics, demonstrating that these pathomechanisms are anatomically regionalized rather than uniform. Finally, we provide a critical evaluation of translation-ready therapeutic targets, emphasizing that strict safety constraints against fetal teratogenesis render ligand-functionalized nanoparticles a non-negotiable prerequisite for placenta-selective drug delivery. Integrating molecular stratification with longitudinal biomarker profiling represents the next milestone for mechanism-based, targeted management of FGR.
- Open Access
- 4 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1281
IGF-1Eb Isoform Immunoreactivity May Be Associated with Placental Dysfunction and Vascular Pathology in Fetal Growth Restriction (FGR)
Background: Fetal growth restriction (FGR) is associated with placental dysfunction and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is important for placental and fetal development, the mRNA expression, immunopositivity and potential biological significance of specific IGF-1 isoforms in FGR remain incompletely characterized. This study investigated placental IGF-1Eb mRNA expression and immunopositivity in FGR pregnancies compared with appropriate-for-gestational-age (AGA) pregnancies. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by FGR and 15 from pregnancies with AGA fetal growth. The mRNA expression of the IGF-1Eb isoform was assessed by reverse-transcription quantitative PCR in a subset of 28 fresh placental samples. IGF-1Eb protein immunoreactivity was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and associations with clinical, demographic, and pathological parameters were evaluated using appropriate statistical analyses. Results: IGF-1Eb mRNA expression did not differ significantly between the FGR and AGA groups. In contrast, significant differences in IGF-1Eb immunoreactivity were observed in selected placental compartments. Moderate immunoreactivity in the perivillous syncytiotrophoblast was more frequent in FGR placentas and was associated with histological features of maternal vascular malperfusion, as well as with gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Increased IGF-1Eb immunopositivity was also observed in the endothelium of maternal decidual and fetal villous vessels in FGR placentas. No significant differences were observed in IGF-1Eb immunoreactivity in the extravillous trophoblast. Conclusions: In this observational study, placental IGF-1Eb protein immunoreactivity, but not mRNA expression, differed between FGR and AGA pregnancies in selected placental compartments. These findings indicate compartment-specific differences in IGF-1Eb protein immunoreactivity, associated with FGR and placental pathological features. However, the observational and cross-sectional design does not establish causality or a functional role for IGF-1Eb in placental dysfunction. Larger prospective studies incorporating functional validation are required to clarify the biological significance of these findings.
- 4 September 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (9) , 1281
Open AccessIGF-1Eb Isoform Immunoreactivity May Be Associated with Placental Dysfunction and Vascular Pathology in Fetal Growth Restriction (FGR)
Background: Fetal growth restriction (FGR) is associated with placental dysfunction and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is important for placental and fetal development, the mRNA expression, immunopositivity and potential biological significance of specific IGF-1 isoforms in FGR remain incompletely characterized. This study investigated placental IGF-1Eb mRNA expression and immunopositivity in FGR pregnancies compared with appropriate-for-gestational-age (AGA) pregnancies. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by FGR and 15 from pregnancies with AGA fetal growth. The mRNA expression of the IGF-1Eb isoform was assessed by reverse-transcription quantitative PCR in a subset of 28 fresh placental samples. IGF-1Eb protein immunoreactivity was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and associations with clinical, demographic, and pathological parameters were evaluated using appropriate statistical analyses. Results: IGF-1Eb mRNA expression did not differ significantly between the FGR and AGA groups. In contrast, significant differences in IGF-1Eb immunoreactivity were observed in selected placental compartments. Moderate immunoreactivity in the perivillous syncytiotrophoblast was more frequent in FGR placentas and was associated with histological features of maternal vascular malperfusion, as well as with gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Increased IGF-1Eb immunopositivity was also observed in the endothelium of maternal decidual and fetal villous vessels in FGR placentas. No significant differences were observed in IGF-1Eb immunoreactivity in the extravillous trophoblast. Conclusions: In this observational study, placental IGF-1Eb protein immunoreactivity, but not mRNA expression, differed between FGR and AGA pregnancies in selected placental compartments. These findings indicate compartment-specific differences in IGF-1Eb protein immunoreactivity, associated with FGR and placental pathological features. However, the observational and cross-sectional design does not establish causality or a functional role for IGF-1Eb in placental dysfunction. Larger prospective studies incorporating functional validation are required to clarify the biological significance of these findings.
- Open Access
- 31 July 2026
- Published by Spandidos Publications in Medicine International
- Vol. 6 (5) , 1-8
Ultrasonographic diagnosis and laparoscopic management of an interstitial ectopic pregnancy: A case report and literature review
Interstitial ectopic pregnancy is a rare yet potentially life‑threatening type of ectopic gestation, representing ~2‑4% of all ectopic pregnancies. As implantation occurs within the interstitial portion of the fallopian tube, the clinical presentation is often delayed, and the risk of a catastrophic hemorrhage is increased in the event that rupture occurs due to its intramural location. Early and accurate diagnosis with high‑resolution transvaginal ultrasonography (TVUS) is thus essential to improve outcomes and preserve fertility. The present case report describes the clinical course of a 35‑year‑old woman (gravida 2, para 1) who presented with prolonged vaginal bleeding and recent‑onset hypogastric pain. Serum β‑human chorionic gonadotropin (β‑hCG) levels plateaued just below 1,000 mIU/ml. TVUS revealed an empty uterine cavity, a thin endometrium and an eccentrically located, mixed‑echogenicity mass within the right uterine cornu, clearly separate from the endometrial cavity. Key sonographic findings included the interstitial line sign, marked asymmetric thinning of the myometrial mantle surrounding the gestational sac to <5 mm and the absence of an adjacent endometrium. Color Doppler imaging demonstrated mild peripheral vascularity. Emergency laparoscopy confirmed an unruptured interstitial pregnancy lateral to the right round ligament. A laparoscopic wedge resection of the interstitial segment was successfully performed, with local vasopressin administration to minimize intraoperative blood loss. The post‑operative course of the patient was uneventful, with a rapid decline in β‑hCG levels and no requirement for adjuvant methotrexate therapy. On the whole, the present case report underscores the critical role of high‑resolution TVUS in the early diagnosis of interstitial pregnancy, and highlights the safety and efficacy of minimally invasive laparoscopic excision in hemodynamically stable patients with unruptured interstitial gestations. Early recognition and individualized surgical management are essential for optimizing clinical outcomes and preserving fertility in this rare condition.
- 31 July 2026
- Published by Spandidos Publications in Medicine International
- Vol. 6 (5) , 1-8
Open AccessUltrasonographic diagnosis and laparoscopic management of an interstitial ectopic pregnancy: A case report and literature review
Interstitial ectopic pregnancy is a rare yet potentially life‑threatening type of ectopic gestation, representing ~2‑4% of all ectopic pregnancies. As implantation occurs within the interstitial portion of the fallopian tube, the clinical presentation is often delayed, and the risk of a catastrophic hemorrhage is increased in the event that rupture occurs due to its intramural location. Early and accurate diagnosis with high‑resolution transvaginal ultrasonography (TVUS) is thus essential to improve outcomes and preserve fertility. The present case report describes the clinical course of a 35‑year‑old woman (gravida 2, para 1) who presented with prolonged vaginal bleeding and recent‑onset hypogastric pain. Serum β‑human chorionic gonadotropin (β‑hCG) levels plateaued just below 1,000 mIU/ml. TVUS revealed an empty uterine cavity, a thin endometrium and an eccentrically located, mixed‑echogenicity mass within the right uterine cornu, clearly separate from the endometrial cavity. Key sonographic findings included the interstitial line sign, marked asymmetric thinning of the myometrial mantle surrounding the gestational sac to <5 mm and the absence of an adjacent endometrium. Color Doppler imaging demonstrated mild peripheral vascularity. Emergency laparoscopy confirmed an unruptured interstitial pregnancy lateral to the right round ligament. A laparoscopic wedge resection of the interstitial segment was successfully performed, with local vasopressin administration to minimize intraoperative blood loss. The post‑operative course of the patient was uneventful, with a rapid decline in β‑hCG levels and no requirement for adjuvant methotrexate therapy. On the whole, the present case report underscores the critical role of high‑resolution TVUS in the early diagnosis of interstitial pregnancy, and highlights the safety and efficacy of minimally invasive laparoscopic excision in hemodynamically stable patients with unruptured interstitial gestations. Early recognition and individualized surgical management are essential for optimizing clinical outcomes and preserving fertility in this rare condition.
- Open Access
Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies
Obesity is a multifactorial condition that profoundly affects female reproductive health through endocrine, metabolic, and inflammatory mechanisms that disrupt the hypothalamic–pituitary–gonadal (HPG) axis. Women with obesity frequently develop menstrual irregularities, anovulation, amenorrhea, infertility, polycystic ovary syndrome (PCOS), impaired endometrial receptivity, and adverse pregnancy outcomes. Central obesity and insulin resistance contribute to hyperinsulinemia, reduced sex hormone-binding globulin (SHBG) levels, hyperandrogenism, altered gonadotropin secretion, and impaired folliculogenesis, while adipokines such as leptin and chronic inflammation further impair ovarian steroidogenesis and ovulatory function. Obesity-related oxidative stress and lipotoxicity also negatively affect oocyte quality, embryo development, implantation, and assisted reproductive technology outcomes, increasing the risk of gestational diabetes, preeclampsia, miscarriage, and preterm birth. This review evaluates the therapeutic potential of pharmacological weight-loss therapies in obesity-associated female reproductive dysfunction. A comprehensive literature review was conducted using various databases, focusing on anti-obesity pharmacotherapy on obesity, infertility and fertility in reproductive-aged women. Evidence suggests that several FDA-approved and off-label anti-obesity agents, including orlistat, liraglutide, semaglutide, phentermine/topiramate, bupropion/naltrexone, metformin, exenatide, and tirzepatide, may improve reproductive outcomes primarily indirectly through weight reduction and metabolic improvement. GLP-1 receptor agonists, particularly liraglutide, semaglutide, and exenatide, appear especially promising, demonstrating beneficial effects on insulin sensitivity, menstrual regularity, ovulation, androgen levels, and pregnancy rates in women with PCOS. Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown potent weight-loss and metabolic effects with potential indirect fertility benefits. Metformin improves insulin sensitivity and is widely used in PCOS to regulate androgen levels and restore ovulation, although its effects on pregnancy and live birth rates remain controversial. However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy. Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required.
Open AccessTherapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction: Translating Mechanistic Evidence into Personalized Clinical Strategies
Obesity is a multifactorial condition that profoundly affects female reproductive health through endocrine, metabolic, and inflammatory mechanisms that disrupt the hypothalamic–pituitary–gonadal (HPG) axis. Women with obesity frequently develop menstrual irregularities, anovulation, amenorrhea, infertility, polycystic ovary syndrome (PCOS), impaired endometrial receptivity, and adverse pregnancy outcomes. Central obesity and insulin resistance contribute to hyperinsulinemia, reduced sex hormone-binding globulin (SHBG) levels, hyperandrogenism, altered gonadotropin secretion, and impaired folliculogenesis, while adipokines such as leptin and chronic inflammation further impair ovarian steroidogenesis and ovulatory function. Obesity-related oxidative stress and lipotoxicity also negatively affect oocyte quality, embryo development, implantation, and assisted reproductive technology outcomes, increasing the risk of gestational diabetes, preeclampsia, miscarriage, and preterm birth. This review evaluates the therapeutic potential of pharmacological weight-loss therapies in obesity-associated female reproductive dysfunction. A comprehensive literature review was conducted using various databases, focusing on anti-obesity pharmacotherapy on obesity, infertility and fertility in reproductive-aged women. Evidence suggests that several FDA-approved and off-label anti-obesity agents, including orlistat, liraglutide, semaglutide, phentermine/topiramate, bupropion/naltrexone, metformin, exenatide, and tirzepatide, may improve reproductive outcomes primarily indirectly through weight reduction and metabolic improvement. GLP-1 receptor agonists, particularly liraglutide, semaglutide, and exenatide, appear especially promising, demonstrating beneficial effects on insulin sensitivity, menstrual regularity, ovulation, androgen levels, and pregnancy rates in women with PCOS. Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown potent weight-loss and metabolic effects with potential indirect fertility benefits. Metformin improves insulin sensitivity and is widely used in PCOS to regulate androgen levels and restore ovulation, although its effects on pregnancy and live birth rates remain controversial. However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy. Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required.
- Open Access
- 1 July 2026
- Published by MDPI AG in Preprints.org
IGF-1Eb Isoform May Be Associated with Placental Dysfunction and Vascular Pathology in Idiopathic Intrauterine Growth Restriction (IUGR)
Background: Idiopathic intrauterine growth restriction (IUGR) is strongly associated with placental dysfunction, impaired spiral uterine artery remodeling, and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is essential for placental and fetal development, the role of specific IGF-1 isoforms remains unclear. This study investigated placental IGF-1Eb expression in idiopathic IUGR and its potential as a biomarker of placental dysfunction. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by idiopathic intrauterine growth restriction (IUGR) and 15 from pregnancies with appropriate-for-gestational-age (AGA) fetal growth, which served as the control group. The mRNA expression levels of the IGF-1Eb isoform were assessed by reverse transcription quantitative PCR in a subset of 28 fresh placental samples. The immunoexpression of IGF-1Eb protein was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and correlations with clinical, demographic and pathological parameters were assessed using appropriate statistical analyses. Results: The mRNA expression of the IGF-1Eb isoform in placentas did not differ significantly between the IUGR and AGA groups. In contrast, immunohistochemical analysis revealed statistically significant differences in IGF-1Eb protein expression. The protein localization was cytoplasmic, perimembranous and occasionally nuclear, expressed in the perivillous and extravillous trophoblast, and the endothelium of fetal and maternal vessels. Moderate IGF-1Eb immunoexpression in the perivillous syncytiotrophoblast was observed significantly more frequently in IUGR placentas compared with the AGA group and was associated with histological changes of maternal vascular malperfusion, and with clinical parameters, including gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Furthermore, a significant increase in IGF-1Eb immunopositivity was observed in the endothelium of maternal decidual and fetal villous vessels in IUGR placentas. In contrast, no statistically significant differences were recorded in the scores or intensity of IGF-1Eb immunoexpression in the extravillous trophoblast between the two groups. Conclusions: Although total IGF-1Eb mRNA levels remained unchanged, increased protein immunoexpression was associated with idiopathic IUGR in distinct parts of the placenta. In association with histological changes of maternal vascular malperfusion, these findings suggest that IGF-1Eb may serve as a potential marker of placental dysfunction in IUGR pregnancies.
- 1 July 2026
- Published by MDPI AG in Preprints.org
Open AccessIGF-1Eb Isoform May Be Associated with Placental Dysfunction and Vascular Pathology in Idiopathic Intrauterine Growth Restriction (IUGR)
Background: Idiopathic intrauterine growth restriction (IUGR) is strongly associated with placental dysfunction, impaired spiral uterine artery remodeling, and adverse perinatal outcomes. Although insulin-like growth factor-1 (IGF-1) signaling is essential for placental and fetal development, the role of specific IGF-1 isoforms remains unclear. This study investigated placental IGF-1Eb expression in idiopathic IUGR and its potential as a biomarker of placental dysfunction. Methods: A total of 62 third-trimester human placentas were analyzed, including 47 from pregnancies complicated by idiopathic intrauterine growth restriction (IUGR) and 15 from pregnancies with appropriate-for-gestational-age (AGA) fetal growth, which served as the control group. The mRNA expression levels of the IGF-1Eb isoform were assessed by reverse transcription quantitative PCR in a subset of 28 fresh placental samples. The immunoexpression of IGF-1Eb protein was assessed in paraffin-embedded tissue sections. Histopathological lesions were classified according to the Amsterdam criteria, and correlations with clinical, demographic and pathological parameters were assessed using appropriate statistical analyses. Results: The mRNA expression of the IGF-1Eb isoform in placentas did not differ significantly between the IUGR and AGA groups. In contrast, immunohistochemical analysis revealed statistically significant differences in IGF-1Eb protein expression. The protein localization was cytoplasmic, perimembranous and occasionally nuclear, expressed in the perivillous and extravillous trophoblast, and the endothelium of fetal and maternal vessels. Moderate IGF-1Eb immunoexpression in the perivillous syncytiotrophoblast was observed significantly more frequently in IUGR placentas compared with the AGA group and was associated with histological changes of maternal vascular malperfusion, and with clinical parameters, including gestational age, neonatal birth weight, placental weight, maternal body mass index, and fetal sex. Furthermore, a significant increase in IGF-1Eb immunopositivity was observed in the endothelium of maternal decidual and fetal villous vessels in IUGR placentas. In contrast, no statistically significant differences were recorded in the scores or intensity of IGF-1Eb immunoexpression in the extravillous trophoblast between the two groups. Conclusions: Although total IGF-1Eb mRNA levels remained unchanged, increased protein immunoexpression was associated with idiopathic IUGR in distinct parts of the placenta. In association with histological changes of maternal vascular malperfusion, these findings suggest that IGF-1Eb may serve as a potential marker of placental dysfunction in IUGR pregnancies.
- Open Access
- 26 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (6) , 557
Antioxidant Polymeric and Non-Polymeric Nanoformulations for the Treatment of Autoimmune Diseases
Autoimmune diseases are characterized by chronic inflammation, immune dysregulation, and excessive oxidative stress, which collectively contribute to a progressive tissue damage and organ dysfunction. Although conventional immunosuppressive and anti-inflammatory therapies remain the main therapeutic approach, their clinical efficacy is often limited by poor pharmacokinetic properties, low tissue selectivity, systemic toxicity, and adverse effects following long-term administration. In this context, antioxidant-based nanoformulations have emerged as promising multi-target therapeutic strategies for the modulation of oxidative and inflammatory pathways involved in autoimmune disorders. This review focuses on polymeric and non-polymeric nanoformulations designed to improve the solubility, stability, bioavailability, controlled release, and targeted delivery of antioxidant and anti-inflammatory agents for autoimmune disease treatment. Recent advances in nanocarrier systems applications, including nanogels, poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), polymethacrylate, chitosan, hyaluronic acid, hydroxyapatite (HAP), lipid-based and ROS-responsive nanosystems, are discussed. The therapeutic potential of nanoencapsulated steroidal and non-steroidal anti-inflammatory drugs, antioxidant compounds, enzymes, inorganic elements, and nucleic acid-binding systems is evaluated through preclinical and limited clinical evidence. Many of these reported nanoformulations exhibit enhanced therapeutic efficacy, improved tissue targeting, reduced systemic toxicity, and the ability to simultaneously modulate oxidative stress and inflammatory signaling pathways. Despite the encouraging findings, important challenges remain regarding clinical translation, long-term safety, reproducibility, and large-scale production. In overall, antioxidant nanoformulations represent a promising and evolving platform for the development of more effective and targeted therapies against autoimmune diseases.
- 26 May 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (6) , 557
Open AccessAntioxidant Polymeric and Non-Polymeric Nanoformulations for the Treatment of Autoimmune Diseases
Autoimmune diseases are characterized by chronic inflammation, immune dysregulation, and excessive oxidative stress, which collectively contribute to a progressive tissue damage and organ dysfunction. Although conventional immunosuppressive and anti-inflammatory therapies remain the main therapeutic approach, their clinical efficacy is often limited by poor pharmacokinetic properties, low tissue selectivity, systemic toxicity, and adverse effects following long-term administration. In this context, antioxidant-based nanoformulations have emerged as promising multi-target therapeutic strategies for the modulation of oxidative and inflammatory pathways involved in autoimmune disorders. This review focuses on polymeric and non-polymeric nanoformulations designed to improve the solubility, stability, bioavailability, controlled release, and targeted delivery of antioxidant and anti-inflammatory agents for autoimmune disease treatment. Recent advances in nanocarrier systems applications, including nanogels, poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), polymethacrylate, chitosan, hyaluronic acid, hydroxyapatite (HAP), lipid-based and ROS-responsive nanosystems, are discussed. The therapeutic potential of nanoencapsulated steroidal and non-steroidal anti-inflammatory drugs, antioxidant compounds, enzymes, inorganic elements, and nucleic acid-binding systems is evaluated through preclinical and limited clinical evidence. Many of these reported nanoformulations exhibit enhanced therapeutic efficacy, improved tissue targeting, reduced systemic toxicity, and the ability to simultaneously modulate oxidative stress and inflammatory signaling pathways. Despite the encouraging findings, important challenges remain regarding clinical translation, long-term safety, reproducibility, and large-scale production. In overall, antioxidant nanoformulations represent a promising and evolving platform for the development of more effective and targeted therapies against autoimmune diseases.
- Open Access
- 26 May 2026
- Published by MDPI AG in Preprints.org
Therapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction
Obesity is a multifactorial condition that profoundly affects female reproductive health through endocrine, metabolic, and inflammatory mechanisms that disrupt the hypothalamic–pituitary–gonadal (HPG) axis. Women with obesity frequently develop menstrual irregularities, anovulation, amenorrhea, infertility, polycystic ovary syndrome (PCOS), impaired endometrial receptivity, and adverse pregnancy outcomes. Central obesity and insulin resistance contribute to hyperinsulinemia, reduced sex hormone-binding globulin (SHBG) levels, hyperandrogenism, altered gonadotropin secretion, and impaired folliculogenesis, while adipokines such as leptin and chronic inflammation further impair ovarian steroidogenesis and ovulatory function. Obesity-related oxidative stress and lipotoxicity also negatively affect oocyte quality, embryo development, implantation, and assisted reproductive technology outcomes, increasing the risk of gestational diabetes, preeclampsia, miscarriage, and preterm birth. This review evaluates the therapeutic potential of pharmacological weight-loss therapies in obesity-associated female reproductive dysfunction. A comprehensive literature review was conducted using Medline, and Google Scholar, focusing on obesity, infertility, fertility, and anti-obesity pharmacotherapy in reproductive-aged women. Evidence suggests that several FDA-approved and off-label anti-obesity agents, including orlistat, liraglutide, semaglutide, phentermine/topiramate, bupropion/ naltrexone, metformin, exenatide, and tirzepatide, may improve reproductive outcomes primarily through weight reduction and metabolic improvement. GLP-1 receptor agonists, particularly liraglutide, semaglutide, and exenatide, appear especially promising, demonstrating beneficial effects on insulin sensitivity, menstrual regularity, ovulation, androgen levels, and pregnancy rates in women with PCOS. Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown potent weight-loss and metabolic effects with potential indirect fertility benefits. Metformin improves insulin sensitivity and is widely used in PCOS to regulate androgen levels and restore ovulation, although its effects on pregnancy and live birth rates remain controversial. However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy. Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required.
- 26 May 2026
- Published by MDPI AG in Preprints.org
Open AccessTherapeutic Potential of Anti-Obesity Drugs in Obesity-Associated Female Reproductive Dysfunction
Obesity is a multifactorial condition that profoundly affects female reproductive health through endocrine, metabolic, and inflammatory mechanisms that disrupt the hypothalamic–pituitary–gonadal (HPG) axis. Women with obesity frequently develop menstrual irregularities, anovulation, amenorrhea, infertility, polycystic ovary syndrome (PCOS), impaired endometrial receptivity, and adverse pregnancy outcomes. Central obesity and insulin resistance contribute to hyperinsulinemia, reduced sex hormone-binding globulin (SHBG) levels, hyperandrogenism, altered gonadotropin secretion, and impaired folliculogenesis, while adipokines such as leptin and chronic inflammation further impair ovarian steroidogenesis and ovulatory function. Obesity-related oxidative stress and lipotoxicity also negatively affect oocyte quality, embryo development, implantation, and assisted reproductive technology outcomes, increasing the risk of gestational diabetes, preeclampsia, miscarriage, and preterm birth. This review evaluates the therapeutic potential of pharmacological weight-loss therapies in obesity-associated female reproductive dysfunction. A comprehensive literature review was conducted using Medline, and Google Scholar, focusing on obesity, infertility, fertility, and anti-obesity pharmacotherapy in reproductive-aged women. Evidence suggests that several FDA-approved and off-label anti-obesity agents, including orlistat, liraglutide, semaglutide, phentermine/topiramate, bupropion/ naltrexone, metformin, exenatide, and tirzepatide, may improve reproductive outcomes primarily through weight reduction and metabolic improvement. GLP-1 receptor agonists, particularly liraglutide, semaglutide, and exenatide, appear especially promising, demonstrating beneficial effects on insulin sensitivity, menstrual regularity, ovulation, androgen levels, and pregnancy rates in women with PCOS. Tirzepatide, a dual GLP-1/GIP receptor agonist, has shown potent weight-loss and metabolic effects with potential indirect fertility benefits. Metformin improves insulin sensitivity and is widely used in PCOS to regulate androgen levels and restore ovulation, although its effects on pregnancy and live birth rates remain controversial. However, evidence for several agents remains limited, and concerns persist regarding reproductive safety during pregnancy. Overall, anti-obesity pharmacotherapy may represent an important adjunctive strategy for improving reproductive and metabolic health in women with obesity, although larger randomized clinical trials are still required.
- Open Access
- 12 May 2026
- Published by Spandidos Publications in Medicine International
- Vol. 6 (4) , 1-9
Ultrasonographic whirlpool sign in ovarian torsion with dual mature teratomas: A case report and literature review
Adnexal torsion is a gynecological emergency resulting from the partial or complete rotation of the ovary, often involving the fallopian tube, around its vascular pedicle. Prompt diagnosis is crucial to prevent ischemic injury and preserve ovarian function. Mature cystic ovarian teratomas are common benign neoplasms and represent a frequent cause of torsion due to their size, mobility and mass effect. The present case report describes the case of a 36‑year‑old woman (gravida 2, para 2) who presented several hours following the sudden onset of right lower abdominal pain, initially accompanied by nausea, both of which had resolved by the time of evaluation. A transvaginal ultrasonography revealed a right ovarian mass measuring 6.13x5.20 cm, containing two mature cystic teratomas. Gray‑scale and color Doppler imaging clearly demonstrated the characteristic whirlpool sign, indicating torsion of the adnexal vascular pedicle. An emergency laparoscopy revealed the quadruple torsion of the adnexa (fallopian tube and ovary), and a right salpingo‑oophorectomy was performed, as the patient had completed her family. The post‑operative course of the patient was uneventful. A post‑operative pathological examination confirmed the torsion of mature ovarian teratomas with associated hemorrhagic necrosis. On the whole, the present study demonstrates that the ultrasonographic whirlpool sign is a highly specific pre‑operative marker for adnexal torsion, particularly in cases with multiple mature cystic teratomas. Early recognition facilitates prompt surgical intervention, minimizes ischemic injury, and may preserve ovarian function. Incorporating the focused assessment of the whirlpool sign into routine ultrasonography for acute pelvic pain enhances diagnostic accuracy and guides timely operative management.
- 12 May 2026
- Published by Spandidos Publications in Medicine International
- Vol. 6 (4) , 1-9
Open AccessUltrasonographic whirlpool sign in ovarian torsion with dual mature teratomas: A case report and literature review
Adnexal torsion is a gynecological emergency resulting from the partial or complete rotation of the ovary, often involving the fallopian tube, around its vascular pedicle. Prompt diagnosis is crucial to prevent ischemic injury and preserve ovarian function. Mature cystic ovarian teratomas are common benign neoplasms and represent a frequent cause of torsion due to their size, mobility and mass effect. The present case report describes the case of a 36‑year‑old woman (gravida 2, para 2) who presented several hours following the sudden onset of right lower abdominal pain, initially accompanied by nausea, both of which had resolved by the time of evaluation. A transvaginal ultrasonography revealed a right ovarian mass measuring 6.13x5.20 cm, containing two mature cystic teratomas. Gray‑scale and color Doppler imaging clearly demonstrated the characteristic whirlpool sign, indicating torsion of the adnexal vascular pedicle. An emergency laparoscopy revealed the quadruple torsion of the adnexa (fallopian tube and ovary), and a right salpingo‑oophorectomy was performed, as the patient had completed her family. The post‑operative course of the patient was uneventful. A post‑operative pathological examination confirmed the torsion of mature ovarian teratomas with associated hemorrhagic necrosis. On the whole, the present study demonstrates that the ultrasonographic whirlpool sign is a highly specific pre‑operative marker for adnexal torsion, particularly in cases with multiple mature cystic teratomas. Early recognition facilitates prompt surgical intervention, minimizes ischemic injury, and may preserve ovarian function. Incorporating the focused assessment of the whirlpool sign into routine ultrasonography for acute pelvic pain enhances diagnostic accuracy and guides timely operative management.